Emergent BioSolutions (EBS) EBT (2011 - 2026)

Emergent BioSolutions' EBT history runs 16 years deep, the most recent figure standing at $13.4 million for Q1 2026.

• In Q1 2026, EBT fell 85.54% year-over-year to $13.4 million; the TTM figure through Mar 2026 stood at $3.5 million (up 105.62% YoY), while the FY2025 annual figure was $82.8 million, up 157.94% from the prior year.
• EBT was $13.4 million for Q1 2026 at Emergent BioSolutions, up from -$50.7 million in the prior quarter.
• In the past five years, EBT ranged from a high of $142.4 million in Q3 2024 to a low of -$269.8 million in Q2 2024.
• Historically, EBT has averaged -$58.4 million across 5 years, with a median of -$50.7 million in 2025.
• The sharpest annual moves came in 2023 and 2025: EBT tumbled 4126.32% in 2023, then surged 666.12% in 2025.
• A 5-year view of EBT shows it stood at -$61.4 million in 2022, then advanced by 11.24% to -$54.5 million in 2023, then surged by 49.36% to -$27.6 million in 2024, then tumbled by 83.7% to -$50.7 million in 2025, then soared by 126.43% to $13.4 million in 2026.
• The last three EBT figures came in at $13.4 million (Q1 2026), -$50.7 million (Q4 2025), and $57.6 million (Q3 2025), per Business Quant data.